SCHEMBL7899677

SCHEMBL7899677

O=C(N1CCN(c2ccc(F)cc2)CC1)N1CCC(C(=O)NC(c2ccc(F)cc2)C(F)(F)F)(c2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 2/20 0.47
PANK3 Q9H999 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
POLB P06746 2/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
GLA P06280 1/20 0.39
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
ME2 P23368 1/20 0.38
ME1 P48163 1/20 0.38
ME3 Q16798 1/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7908737 0.86 PANK3 (0.48) AKR1C3PANK3NPSR1POLBCA12
SCHEMBL7912655 0.84 PANK3 (0.47) AKR1C3PANK3NPSR1POLBCA12
SCHEMBL378278 0.82 NPSR1 (0.50) AKR1C3PANK3NPSR1POLBSMN1; SMN2
SCHEMBL13102899 0.80 AKR1C3 (0.44) AKR1C3PANK3NPSR1POLBCA12
SCHEMBL7900653 0.80 PTPN1 (0.42) POLBMAPT
SCHEMBL379204 0.80 NPSR1 (0.50) AKR1C3PANK3NPSR1POLBSMN1; SMN2
SCHEMBL7909141 0.79 KIT (0.44) AKR1C3PANK3NPSR1POLBSMN1; SMN2
SCHEMBL7910246 0.79 AKR1C3 (0.52) AKR1C3NPSR1POLBCA12CA1
SCHEMBL7899679 0.78 AKR1C3 (0.51) AKR1C3PANK3NPSR1POLBCA12
SCHEMBL378652 0.78 AKR1C3 (0.59) AKR1C3NPSR1POLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 AKR1C3 1724/4885PANK3 684/4885NPSR1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.